Cargando cotizaciones...
Previsión
| Comprar |
4 |
| Mantener |
2 |
| Vender |
0 |
Noticias Ir al feed de noticias
Check-Cap conducts 1-for-7 reverse stock split
Check-Cap will carry out a 1-for-7 reverse stock split on Wednesday, reducing outstanding common shares from about 9,463,062 to approximately 1,351,866. The common shares will remain listed on the Nasdaq Capital Market under the ticker MBAI and will be quoted adjusted for the split at the market open; the new CUSIP is M6S83C106. Fractional shares will be rounded up, and registered and brokerage-account shareholders do not need to take any action. The measure was approved by the board of directors and ratified by shareholders and is being undertaken in preparation for the planned merger with MBody AI, scheduled for Q3 2026 and still subject to Nasdaq approvals and customary closing conditions. » Más en de.investing.com
Check-Cap submits audited financial statements of MBody AI and targets merger for H1 2026
Check-Cap has filed financial reports with the SEC in connection with the planned merger with MBody AI and confirmed that preparations for the combination are continuing. The merger, already approved by Check-Cap shareholders on November 14, 2025, foresees MBody AI becoming a wholly owned subsidiary of Check-Cap. Check-Cap provided audited financial statements of MBody AI as of December 31, 2025, supplemented by unaudited pro forma financial information for the combined company. Closing is targeted for the first half of 2026 but is contingent on capital availability to meet NASDAQ requirements as well as regulatory and exchange reviews, with no guarantee of completion. » Más en de.investing.com
Check-Cap meets NASDAQ minimum capital rule after adjustment to loan receivable
Check-Cap says it now complies with NASDAQ listing rule 5550(b)(1) after restoring the collectible portion of a loan receivable from Apollo Technology Capital Corporation. According to unaudited financial statements for June 30, 2025, filed with the SEC on December 30, 2025, shareholders’ equity exceeds the required $2.5 million threshold. NASDAQ will continue to monitor compliance; delisting remains possible if Check-Cap fails to meet the rules in its next periodic report, though the company expects to be in compliance. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | 2024 | |
|---|---|---|
| Ingresos | 0,00 | - |
| Beneficio bruto | −154,72k | 19,32% |
| Beneficio neto | −24,17M | 52,08% |
| EBITDA | −8,94M | 44,01% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 9,34M€ |
Número de acciones | 5,85M |
Máximo/mínimo de 52 semanas | 2,69€ - 0,48€ |
| Dividendos | No |
Beta | 0,46 |
Ratio P/E | 1,73 |
Ratio PEG | 0,02 |
Ratio P/B | 2,07 |
Ratio P/S | 0,00 |
Perfil de la empresa
Check-Cap Ltd. ist ein medizinisches Diagnostikunternehmen in der klinischen Phase, das sich mit der Entwicklung einer kapselbasierten Screening-Technologie befasst, die ultra-niedrige Röntgenstrahlen verwendet, um die innere Auskleidung des Dickdarms auf präkanzeröse Polypen und andere strukturelle Anomalien in Israel zu untersuchen. Das C-Scan-System besteht aus der C-Scan Cap, einer Röntgenkapsel zur Erkennung von Polypenverdacht, dem C-Scan Track, einem Einwegsystem, das mit Hilfe von biokompatiblen Klebepflastern auf dem Rücken des Patienten befestigt wird, und der C-Scan View Software, einer Client/Server-basierten Anwendung, die das Herunterladen von Verfahrensdaten vom C-Scan Track, die Datenanalyse und die Berichterstellung ermöglicht. Das Unternehmen wurde im Jahr 2004 gegründet und hat seinen Sitz in Isfiya, Israel.
| Nombre | Check-Cap |
| CEO | David Lontini |
| Sede | Isfiya,
Israel |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 04/03/2015 |
| Empleados | 85 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | CHEK |
Frankfurt | 7CC.F |
München | 7CC.MU |
Descubrir activos
Los accionistas de Check-Cap también invierten en los siguientes activos

